FABP5 and prostate carcinoma: In vitro studies have demonstrated that genetic knockdown or silencing of FABP5 inhibits prostate cancer cell proliferation and invasiveness and that inhibitors targeting FABP5 exert synergistic effects with taxanes, leading to decreased tumor growth and metastasis [21].